Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Active immunization against hepatitis B].

H J Wildgrube, M Classen, R von Lohr

    Deutsche Medizinische Wochenschrift (1946)
    |February 17, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers.

    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2005
    Same author

    [Helicobacter eradication: an expensive Sisyphus task].

    Medizinische Klinik (Munich, Germany : 1983)·1998
    Same author

    Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors.

    AIDS (London, England)·1997
    Same author

    [Aids].

    Pharmazie in unserer Zeit·1997
    Same author

    Viral safety of a new highly purified factor VIII (OCTATE).

    Journal of medical virology·1996
    Same author

    Influenza vaccines.

    International archives of allergy and immunology·1995
    Same journal

    Deutsche medizinische Wochenschrift (1946)·2026
    Same journal

    ["Not everything that looks like a tumor..." - Pulmonary tularemia with hilar lymphadenopathy].

    Deutsche medizinische Wochenschrift (1946)·2026
    Same journal

    [Emergency management of sickle cell disease].

    Deutsche medizinische Wochenschrift (1946)·2026
    Same journal

    [Hereditary dehydrated stomatocytosis (= hereditary xerocytosis) - Interesting hummingbird or clinically relevant diagnosis?]

    Deutsche medizinische Wochenschrift (1946)·2026
    Same journal

    [Diagnosis of Congenital Hemolytic Anemias in Adults].

    Deutsche medizinische Wochenschrift (1946)·2026
    Same journal

    [46-year-old female patient with right upper abdominal pain].

    Deutsche medizinische Wochenschrift (1946)·2026
    See all related articles

    The Hevac B Pasteur hepatitis B vaccine is safe and effective, with 93.1% of recipients developing protective antibodies within six months. Antibody response varied by sex and age, with females and younger individuals showing higher initial rates.

    Area of Science:

    • Immunology
    • Vaccinology
    • Hepatology

    Context:

    • Hepatitis B virus (HBV) infection remains a significant global health concern.
    • Effective vaccination strategies are crucial for preventing HBV transmission and chronic infection.
    • The Hevac B Pasteur vaccine is a key tool in hepatitis B prevention efforts.

    Purpose:

    • To evaluate the immunogenicity and safety of the Hevac B Pasteur hepatitis B vaccine.
    • To assess seroconversion rates and antibody titers following vaccination.
    • To identify demographic factors influencing vaccine response.

    Summary:

    • A 6-month study assessed the Hevac B Pasteur vaccine in 277 individuals, administered in three monthly 5-microgram doses.
    • Radioimmunological determination of hepatitis B serologic markers showed 85.7% seroconversion within two months and 93.1% after six months.

    Related Experiment Videos

  • Higher anti-HBs levels were initially observed in females but normalized by six months; age significantly impacted seroconversion rates and antibody concentrations.

    • Impact:

    • The Hevac B Pasteur vaccine demonstrates robust immunogenicity and a favorable safety profile.
    • Findings highlight the vaccine's efficacy in inducing protective antibodies against hepatitis B.
    • Understanding demographic influences on vaccine response can inform targeted vaccination strategies.